Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Entered into a definitive agreement to acquire 100% of Kashiv BioSciences, a vertically integrated biopharmaceutical company, pending shareholder and regulatory approvals.

• Acquisition aims to strengthen the biosimilars platform and expand the portfolio of approved, pending, and development-stage biosimilars.

• Transaction is expected to enhance access to affordable biologic medicines in the U.S. and globally.

• Business operations will continue as usual until the transaction closes, with ongoing communication to stakeholders.

Voting matters and shareholder proposals

• Shareholder approval is required for the acquisition of Kashiv BioSciences.

• Proxy statements and related materials will be filed with the SEC and distributed to shareholders for voting.

Board of directors and corporate governance

• Directors, executive officers, and certain employees may participate in the solicitation of proxies for the proposed transaction.

• Information about directors and executive officers is available in the 2026 annual meeting proxy statement.